🔘 Selecting First-Line Therapy for Metastatic Urothelial Carcinoma: Does ‘One Size Fit All’ or Is Customization Needed?

#UrothelialCarcinoma #bladdercancer

buff.ly/4azxVb0

A #GU24 roundtable with Drs. Vadim Koshkin MD, Petros Grivas, Karine Tawagi MD, Terry Friedlander, and Guru P. Sonpavde, MD shared their forward-thinking thoughts on the impending direction of #UrothelialCarcinoma treatment. Learn More: buff.ly/3SSi3K1

Dive into the latest insights from the #UNITE study on targeted agents for advanced #UrothelialCarcinoma with this panel discussion from #GU24 featuring Vadim Koshkin MD, Amanda Nizam, MD, Matt Campbell MD, MS, and Omar Alhalabi, MD. Watch Now: buff.ly/3UWS4Tx

Dr Maria Jiang discusses results of the #CheckMate274 study on patients with muscle-invasive #urothelialcarcinoma . See her full analysis here: ow.ly/PHG850RmNFR

Watch all content from our Best of ASCO®️ GU & GI Cancers conference here: ow.ly/8etL50RmNFS

#MedOnc

#MEDIA : The EU Medicines Agency #CHMP issued a positive opinion for our #immunotherapy -chemotherapy combination as a first-line treatment for adult patients with unresectable or metastatic #urothelialcarcinoma . bit.ly/44kQ1eC

Massive achievement in #BladderCancer #UrothelialCarcinoma .

💡To understand the context of EVP combination, look at this table.
*Data before having maintenance avelumab.

1yOS from 50% ish to 78%. Huge!

authors.elsevier.com/a/1ih5y_ZSJXGt…

#ESMO23 Late breaker: FIH Study #TAR210 intravesical #Erdafitinib delivery system for #FGFR + #UrothelialCarcinoma :
👉High recurrence free/complete response rate
👉11/13 evaluable patients (BCG exp. HR #NMIBC ) + 13/15 (IR #NMIBC ) recurrence free #AntoniVilaseca JNJInnovative Medicine

Michael F. Basin, MD presents a comparative study 👏🤯on #urothelialcarcinoma in the bladder and upper tract with FGFR3 mutation. FGFR3mut+ status is more frequent in advanced TUC than in CUB. Patients with CUB FGFR3mut+ have more genomic co-drivers than those with TUC FGFR3mut+.

Elegant presentation by Sumanta K. Pal - Martín Angel
Sumanta K. Pal, MD, FASCO
oncodaily.com/32153.html

#Cancer #ImmuneCheckpointInhibitors #ICI #OncoDaily #Oncology #UrothelialCarcinoma

Full FDA approval for #Erdafitinib for the treatment of pts with locally advanced/metastatic FGFR+ #UrothelialCarcinoma following prior systemic therapy, based on data from THOR/Cohort 1): 36% risk reduction in death in pts with prior PD1/PDL1 inhibition vs chemo J&J Innovative Medicine

🔘 Selecting First-Line Therapy for Metastatic Urothelial Carcinoma: Does ‘One Size Fit All’ or Is Customization Needed?

#UrothelialCarcinoma #bladdercancer

buff.ly/4azxVb0

Therapeutic Opportunities for Hypermutated Urothelial Carcinomas Beyond Immunotherapy - please check the link for more ow.ly/WhmR50REjHy NOSM University | Université EMNO #UrothelialCarcinoma #CancerResearch #Oncology

#GU24
🌟Very insightful talk from Sumanta K. Pal, MD, FASCO on what we've learnt from other diseases in sequencing of ICIs in #urothelialcarcinoma
➡️Adjuvant therapy is great but is neoadjuvant better? Reminded us of Sapna Patel's melanoma and Heather Wakelee's data from lung cancer.

Different PU Junction and Medial Perirenal Perihilar Masses

These are easy to do percutaneously.

Discussion and video
ctbiopsy.com/case119/

#ctbiopsy #irrad #pelviuretericjunction #PUJ #urothelialcarcinoma #perirenal

Case 119: Pelvi-ureteric junction (PUJ) Mass Biopsy

These are easy to do percutaneously. 63-years old man.

Discussion and video
ctbiopsy.com/case119/

#ctbiopsy #irrad #pelviuretericjunction #PUJ #urothelialcarcinoma

Can successful #Immunotherapies for human #UrothelialCarcinoma also be used to treat pets? Since there are immune-based similarities between species with this disease, it's possible!

🥼 Learn more: ovcclinicaltrials.uoguelph.ca/publications/

🔬Publication link: doi.org/10.1111/vco.12…

Did you know that so far the data presented at #ESMO23 made it to 5️⃣ publications in the NEJM ‼️
#NSCLC #urothelialcarcinoma #melanoma #thyroidcancer
One of the best 👌 congresses so far! This is one of the reasons why you should attend the congress! #excellent #science

Both benign/non-cancerous & malignant/cancerous tumors can arise in the kidney. The most common #KidneyCancer is renal cell carcinoma, followed by #WilmsTumor (found mainly in children), & #UrothelialCarcinoma mainly from the kidney calyces/pelvis.

#KidneyCancer AwarenessMonth

1/7 Treatment of #urothelialcarcinoma #BladderCancer has changed significantly in 2023/2024! Join us 👇for our case wrap up: Guru P. Sonpavde, MD & Jon Anker, MD, PhD review key concepts-
-- Choosing 1L tx in mUC
-- Role of FGFR inhibitor (erda)
-- New approaches coming soon! #TumorBoardTuesday

How to select the correct strategies to personalize the care for advanced #urothelialcarcinoma ?

Join us & discuss with Simon Crabb from ECMC Network Southampton in presence or virtually!

Register for free➡️ow.ly/pMgb50R6xAE

#IUCS24 Giuseppe Banna Ravindran Kanesvaran